Abstract Library

Welcome to the open-access search for all ENETS abstracts presented at the Annual ENETS Conferences.

Everyone can browse the library to find basic information on abstracts. To get full access to each entry, you will be asked to log in to your myENETS account.

 

Please note:

Participants of the 2025 ENETS Conference enjoy full access to the 2025 conference digital resources through myENETS: the abstract booklet, e-posters and videos, slide decks of talks, the poster carousel, and more.

Log in to myENETS

ENETS Abstract Search

#4630 Radiolabelled somatostatin receptor (SSTR) antagonist vs. agonist for peptide receptor radionuclide therapy (PPRT) in patients with SSTR positive neuroendocrine tumours – A retrospective basket study

Introduction: PRRT with lutetium-177 labelled somatostatin receptor (SSTR) agonists ([177Lu]Lu-DOTATATE or [177Lu]Lu-DOTATOC (177Lu-TOC) has limited response rate and durability. The SSTR antagonist [177Lu]Lu-DOTA-JR11 (177Lu-JR11) offers potentially increased tumour doses with better efficacy.

Conference:

Presenting Author: Eigler C

Authors: Eigler C, Mushaweh A, McDougall L, Bauman A, Christ E,

Keywords: Somatostatin Receptor, Neuroendocrine Tumour, DOTA-JR11, DOTA-TOC, Peptide Receptor Radionuclide Therapy,

#4615 Dosimetry, efficacy and safety of radiolabelled somatostatin receptor antagonist in patients with metastatic pheochromocytoma or paraganglioma

Introduction: Metastatic pheochromocytomas and paragangliomas (mPPGLs) are rare neuroendocrine tumours with a heterogenous phenotype and a variable treatment response. The SSTR antagonist [177Lu]Lu177Lu-DOTA-JR11 (177Lu-JR11) offers potentially increased tumour doses than standard radioligand therapy (RLT) with [177Lu]Lu-DOTA-TOC (177Lu-TOC).

Conference:

Presenting Author: Lider S

Authors: Lider Burciulescu S, Schmidt F, McDougall L, Bernhardt P, Mushaweh A,

Keywords: Metastatic PPGL, radioligand therapy, somatostatin receptor antagonist, dosimetry,

#3383 Well-differentiated grade 3 neuroendocrine tumors: Characteristics, treatments and outcomes from a population-based study

Introduction: Well-differentiated grade 3 neuroendocrine tumors (G3 NETs) are a new clinically distinct grouping, however their characteristics, prognosis and treatment outcomes remain unclear.

Conference:

Presenting Author: Boutin M

Authors: Boutin M, Mathews A, Badesha J, Paul A, Safro M,

Keywords: neuroendocrine, grade 3, well-differentiated, treatment, outcome,

#2010 A case of Carcinoid Crisis Despite High Dose Somatostatin Analogue Therapy Peri-operatively

Introduction: Carcinoid crisis is a life threatening endocrine emergency. Somatostatin analogues (SSA) are recommended as prophylactic administration before invasive procedures. It remains unclear whether there is an optimal dose of prophylactic somatostatin analogue therapy in the peri-operative period.

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author:

Authors: Pitfield D, Casey R, Seetho I, Shaw A, Buscombe J,

Keywords: carcinoid syndrome, carcinoid crisis, octreotide, surgery,